Financial Daily from THE HINDU group of publications
Thursday, Oct 02, 2003

Port Info

Group Sites

Corporate - Research & Development

Natco Pharma to cash in on R&D successes

Our Bureau

Hyderabad , Oct. 1

NATCO Pharma Ltd (NPL), the city-based pharmaceutical company known for its time-release technology, has drawn up a strategy of cashing in on the successes recorded by its research and development (R&D) wing and to tap the regulated markets.

Addressing the annual general meeting here, the NPL Chairman and Managing Director, Dr V.C. Nannapaneni, informed the shareholders that the research based upon molecular modelling techniques initiated by the company during the past two years has already resulted in synthesising 20 lead compounds. These were primarily in the fields of anti-cancer, anti-ulcer and anti-depressant segments.

According to Dr Nannapaneni, these compounds were currently in the process of screening and would await pre-clinical trials. Further, the company's efforts in biotechnology were beginning to bear fruits with one molecule based on RDNA technology coming off the lab and advancing into pre-clinical trials and one specialised product based on peptide synthesis about to complete the lab work next only to the innovator and also one fermentation based drug for use in organ transplant also coming through the lab.

Article E-Mail :: Comment :: Syndication

Stories in this Section
Natco Pharma to cash in on R&D successes

GMR Tech gets extension for AGM
Agilent Tech sees scope in food, drugs
USFDA nod for Lupin's Ceftriaxone
BHEL export order booking at Rs 1,455 cr
ABB to supply rectifier systems for Sterlite group
Lockout at HLL unit lifted
Bata to shift marketing base to Delhi
Asahi to delist shares
Havells board meet
ONGC employee's prolonged suspension justified, says Madras HC
MMTC net up 35% at Rs 25 cr
Indian Hotels to make fresh foray into US
Emcure setting up new formulation facility
India Today enters into licensing pact with Reader's Digest
Herbalife lends a helping hand
Certification for pharma co
Sick cos in IDBI, IFCI portfolio up
BIFR issues show-cause notice for winding up IDPL
It's curtains for Hind Antibiotics?
Shareholders give approval to take PHIL Corpn to BIFR
NGEF to make Rs 30-cr retirement settlement
Post-Valtra, PTL... M&M `mission' still on
Slew of domestic launches planned — ITC Foods to tickle overseas palates
D-Link sees $200-m revenue from India
Jindal Photo eyes Rs 500-cr turnover
Satnam Overseas eyes higher basmati exports
Bajaj Auto two, 3-wheeler sales up 18 pc in Sept
Maruti sells more in September
Hyundai sales increase 53 pc
Hero Honda sales up
Gopala Rao is new CMD of BEL

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | Home |

Copyright 2003, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line